Standard fertility evaluations routinely declare patients “normal” within reference ranges derived from sick populations, while optimal thresholds for conception remain unaddressed. Thyroid-stimulating hormone (TSH) levels considered acceptable up to 4.5 mIU/L carry a 2–3× elevated miscarriage risk above 2.5 mIU/L, yet this distinction is rarely communicated to patients. Male factor infertility—contributing to 50% of all infertility cases—receives approximately 5% of diagnostic attention, typically limited to basic semen analysis that misses DNA fragmentation, morphology depth, and motility subtleties. The diagnosis of “unexplained infertility” functions not as a medical finding but as a confession of diagnostic incompleteness: comprehensive evaluation identifies actual causes in 70–85% of these couples.
Key Clinical Takeaways
- TSH “normal” does not mean TSH optimal for fertility — the standard reference range of 0.4–4.5 mIU/L is based on sick population averages; TSH above 2.5 mIU/L increases miscarriage risk 2–3×, while the optimal range for conception and pregnancy is 1.0–2.0 mIU/L
- “Unexplained infertility” is a diagnostic default, not a diagnosis — comprehensive evaluation identifies identifiable causes in 70–85% of couples initially labeled “unexplained,” meaning the label reflects the limits of testing, not the absence of pathology
- Male factor contributes to 50% of infertility yet receives ~5% of diagnostic resources — standard semen analysis evaluates count, motility, and morphology but misses sperm DNA fragmentation (the single most important overlooked test), reactive oxygen species damage, and hidden varicoceles present in 35–40% of men with primary infertility
- Nutrient deficiencies critical for conception are almost never tested — Vitamin D below 30 ng/mL reduces conception probability by 40% per cycle; ferritin below 50 ng/mL impairs ovulation without anemia; B12 below 300 pg/mL significantly increases miscarriage risk—yet these are absent from standard fertility workups
- Reference ranges are statistical averages, not functional thresholds — the clinical consequence of “normal” lab results in a patient with reproductive failure is not reassurance; it is a missed diagnosis
The Reference Range Deception: When “Normal” Is Incompatible With Conception
The most consequential diagnostic failure in reproductive medicine is not the absence of testing—it is the misinterpretation of test results that are performed. The reference ranges printed on laboratory reports represent statistical distributions derived from the tested population, not functional thresholds for optimal reproductive function.
Consider the most pervasive example: thyroid-stimulating hormone.
The standard TSH reference range in most laboratories spans 0.4–4.5 mIU/L. A patient with a TSH of 3.8 mIU/L receives a report marked “normal” with no flag, no asterisk, no indication that anything requires attention. Yet the evidence is unequivocal: TSH levels above 2.5 mIU/L are associated with a 2–3× increase in miscarriage risk, and TSH above 3.5 mIU/L significantly reduces conception rates.
The American Thyroid Association and the Endocrine Society have both acknowledged that preconception TSH should ideally be below 2.5 mIU/L, and clinical evidence increasingly supports an optimal target of 1.0–2.0 mIU/L for fertility and early pregnancy. But the laboratory reference range has not been revised to reflect this evidence, and the majority of clinicians ordering TSH as part of a fertility workup rely on the flagged/normal binary rather than applying reproductive-specific thresholds.
The result is predictable: patients with TSH values of 2.6, 3.2, or 4.0 mIU/L are told their thyroid is “fine” and directed toward assisted reproductive technology without ever addressing the thyroid dysfunction that may be the primary barrier to conception or carrying to term.
The Sick Population Problem
Reference ranges are established by testing large populations and defining the central 95% as “normal.” This methodology has a fundamental flaw when applied to reproductive optimization: the reference population includes individuals with undiagnosed thyroid disease, subclinical hypothyroidism, autoimmune conditions, and nutrient deficiencies. The range is not derived from a healthy, optimally fertile cohort—it is derived from whoever walks into the laboratory.
The NHANES III data demonstrated that when individuals with thyroid antibodies, those on thyroid medication, and those with visible thyroid disease are excluded from the reference population, the upper limit of TSH shifts substantially downward. The “normal” range of 0.4–4.5 mIU/L becomes something closer to 0.4–2.5 mIU/L when the reference population is actually healthy.
For fertility patients, the distinction is not academic. A TSH of 3.5 mIU/L—solidly within the standard reference range—carries measurable reproductive consequences:
- Menstrual irregularities: Even mild hypothyroidism causes luteal phase defects, impaired progesterone production, and cycle disturbances that undermine conception timing
- Miscarriage risk: TSH above 2.5 mIU/L doubles to triples early pregnancy loss
- Conception probability: TSH above 3.5 mIU/L significantly reduces the likelihood of conception per cycle
- Thyroid antibodies: Even with TSH within range, the presence of thyroid peroxidase (TPO) antibodies independently increases miscarriage risk
Yet this patient will routinely be cleared through thyroid assessment and moved to the next station on the IVF conveyor belt.
Beyond TSH: The Full Thyroid Panel
Standard fertility workups that include thyroid assessment typically order TSH alone. A complete thyroid evaluation for fertility must include:
- Free T4: Optimal range 1.0–1.5 ng/dL; essential for peripheral conversion and directly relevant to fetal brain development
- Free T3: Optimal range 3.0–4.0 pg/mL; the active thyroid hormone at the cellular level; low Free T3 despite “normal” TSH indicates conversion failure
- TPO and Tg antibodies: Thyroid antibodies alone—even with TSH below 2.5—increase miscarriage risk and indicate autoimmune thyroid involvement that warrants monitoring and potentially intervention
The omission of Free T3, Free T4, and antibody testing from standard fertility evaluations means that a substantial proportion of thyroid-related fertility impairment goes undetected. The patient with central hypothyroidism, the patient with T4-to-T3 conversion failure, and the patient with autoimmune thyroid disease but currently compensated TSH—all remain invisible under standard testing protocols.
The Male Factor Collapse: 50% of the Problem, 5% of the Attention
Male factor infertility contributes to approximately 50% of all infertility cases—sole cause in 20–30% and contributing factor in another 20–30%. Yet the diagnostic attention and resource allocation devoted to male factor evaluation is a fraction of that directed toward female assessment.
The standard male fertility workup consists of a single test: semen analysis.
A conventional semen analysis reports volume, count, motility, and morphology. While these parameters provide useful baseline information, they represent a profoundly incomplete picture of male reproductive capacity. Two men with identical semen analysis results may have dramatically different fertility potential based on factors the standard analysis cannot assess.
The DNA Fragmentation Gap
Sperm DNA fragmentation (SDF) testing is arguably the single most important overlooked diagnostic in male fertility assessment. DNA fragmentation measures the integrity of the genetic payload the sperm delivers to the oocyte—and it is entirely invisible on standard semen analysis.
A man with normal count, motility, and morphology can have DNA fragmentation rates of 30%, 40%, or 50%—meaning a substantial proportion of his sperm carry damaged DNA that may prevent fertilization, impair embryo development, or increase miscarriage risk.
The clinical implications are significant:
- DNA fragmentation above 30% is associated with reduced fertilization rates, poorer embryo quality, and increased early pregnancy loss
- DNA fragmentation above 50% represents a severe impairment that substantially reduces the probability of successful conception, whether natural or assisted
- Standard IVF with high SDF often results in fertilization and initial embryo development, but implantation failure or early miscarriage—the embryo inherits damaged DNA that manifests after the standard embryology assessment window
The test for DNA fragmentation (SCSA, TUNEL, or Comet assay) is widely available, relatively inexpensive, and provides information that fundamentally alters clinical decision-making. Yet it remains absent from most initial fertility evaluations, reserved—if ordered at all—for couples who have already failed multiple IVF cycles.
This sequencing is clinically backwards. DNA fragmentation should be assessed early, before significant financial and emotional investment in assisted reproduction, because addressing the underlying causes of elevated SDF (varicocele, oxidative stress, toxin exposure, infection, heat exposure) may improve outcomes without requiring IVF at all.
Hidden Varicoceles and the Subclinical Male Factor
Varicoceles—dilated veins in the pampiniform plexus of the scrotum—are present in approximately 15% of the general male population but in 35–40% of men presenting with primary infertility. The mechanism is straightforward: venous congestion increases scrotal temperature, and spermatogenesis is exquisitely temperature-sensitive.
Subclinical varicoceles—those not detectable on physical examination but identifiable on scrotal ultrasound—may represent an even larger hidden population. The standard fertility workup for men does not include scrotal ultrasound. A man with a subclinical varicocele contributing to elevated DNA fragmentation and impaired sperm parameters will have no identifiable findings on the standard evaluation.
The Exogenous Testosterone Trap
One of the most clinically significant and frequently overlooked male factor issues is the use of exogenous testosterone replacement therapy (TRT). Exogenous testosterone—whether delivered via injection, gel, patch, or pellet—suppresses the hypothalamic-pituitary-gonadal axis. The testes receive the signal that circulating testosterone is adequate, and they cease endogenous production, including the cessation of spermatogenesis.
TRT shuts down sperm production in more than 90% of men.
For men who wish to preserve fertility, this information is critical. Yet many men are prescribed testosterone without adequate counseling regarding its contraceptive effects, and many couples presenting with infertility never have the male partner’s testosterone supplementation history adequately reviewed.
The scenario is common: a couple undergoes extensive female evaluation—hysterosalpingography, ovarian reserve testing, cycle monitoring—while the male partner’s testosterone prescription sits unexamined in his medication list, silently eliminating the couple’s chances of natural conception.
The Nutrient Blind Spot: Deficiencies That Directly Impair Conception
Standard fertility evaluations almost universally omit nutritional assessment. This omission is remarkable given the well-documented relationships between specific nutrient deficiencies and reproductive failure.
Vitamin D: The Conception Vitamin
Vitamin D levels below 30 ng/mL are associated with a 40% reduced chance of conception per cycle. The optimal range for conception and pregnancy support is 50–70 ng/mL. Yet Vitamin D testing is not part of the standard fertility workup in most clinics, and patients routinely enter IVF cycles with levels in the teens or twenties—profoundly suboptimal for reproductive function.
Vitamin D receptors are present throughout the reproductive tract: in the ovaries, endometrium, placenta, and decidua. Vitamin D modulates anti-Müllerian hormone (AMH) production, influences follicular development, and participates in immune regulation at the maternal-fetal interface. Deficiency compromises each of these mechanisms simultaneously.
Ferritin: Beyond Anemia
Ferritin levels below 50 ng/mL impair ovulation even in the absence of clinical anemia. Standard fertility panels may check hemoglobin or hematocrit but frequently omit ferritin. A patient with normal hemoglobin but ferritin of 15 ng/mL has profoundly inadequate iron stores for reproductive function—yet she will be told her iron is “fine” based on an incomplete assessment.
Iron is essential for ovulation, dopamine synthesis, thyroid function, and oxygen delivery to the reproductive organs. The distinction between “not anemic” and “iron-replete for fertility” is a gap that standard testing routinely fails to bridge.
B12 and Folate: The MTHFR Connection
Vitamin B12 levels below 300 pg/mL significantly increase miscarriage risk. Standard B12 reference ranges extend down to 200 pg/mL or lower, again reflecting population averages rather than reproductive thresholds.
Moreover, MTHFR mutations—found in more than 40% of recurrent miscarriage cases—impair the conversion of synthetic folic acid to its active form, methylfolate. Women with MTHFR mutations may supplement with folic acid and achieve “normal” folate levels on serum testing while remaining functionally deficient in the methylated form required for DNA synthesis, neural tube closure, and homocysteine metabolism.
The appropriate testing and supplementation strategy—assessing MTHFR status and providing methylated B-vitamins (methylfolate and methylcobalamin)—is rarely part of standard fertility care, despite the substantial evidence supporting its relevance.
“Unexplained Infertility”: The Diagnosis That Explains Nothing
The term “unexplained infertility” is applied when standard evaluation yields no identifiable cause. Standard evaluation, as demonstrated above, includes:
- TSH only (without Free T3, Free T4, or antibodies)
- Basic semen analysis (without DNA fragmentation, strict morphology, or ROS assessment)
- Tubal patency (hysterosalpingography)
- Ovarian reserve (AMH, FSH)
- Cycle monitoring (progesterone, possibly)
This workup—limited in thyroid depth, male factor comprehensiveness, nutritional assessment, immunological screening, infectious disease evaluation, and toxicological analysis—declares the cause “unexplained” when it cannot be found within its narrow scope.
Comprehensive evaluation identifies actual causes in 70–85% of couples labeled “unexplained.”
This statistic is not controversial. It is the logical consequence of looking more thoroughly: when you test for more conditions, you find more causes. The finding of “unexplained infertility” is not a reflection of medical mystery—it is a reflection of diagnostic restraint.
The couples who receive this label are then directed toward IVF, a technology designed to bypass reproductive obstacles rather than identify them. ICSI—intracytoplasmic sperm injection—injects a single sperm directly into the oocyte, circumventing poor sperm motility, morphology, or count without investigating why those parameters are abnormal in the first place.
When the underlying cause remains unaddressed, IVF success rates reflect the consequence: even in women under 35, the live birth rate per cycle is approximately 31.2%. With three cumulative cycles, success approaches 50–60%—meaning IVF fails 40–70% of the time even in the most favorable demographic, often because the unaddressed root cause continues to sabotage implantation, embryo development, or pregnancy maintenance.
The Path Forward: Comprehensive Fertility Evaluation
A fertility evaluation that aspires to identify causes rather than label their absence must include:
Thyroid optimization panel: TSH (target 1.0–2.0 mIU/L), Free T4, Free T3, TPO antibodies, Tg antibodies
Comprehensive male assessment: Semen analysis plus DNA fragmentation (SCSA), strict morphology (Kruger criteria), progressive motility, reactive oxygen species evaluation, scrotal ultrasound for varicocele, hormone panel (testosterone, estradiol, FSH, LH)
Nutrient optimization panel: 25-OH Vitamin D, ferritin, B12, folate, RBC magnesium, selenium, zinc, iodine
Immunological screening: Antiphospholipid antibodies (anticardiolipin, lupus anticoagulant, anti-β2 glycoprotein), natural killer cell activity, antisperm antibodies
Infectious disease evaluation: Chlamydia, Ureaplasma, Mycoplasma, and consideration of chronic viral burden in relevant clinical contexts
Toxicological assessment: Heavy metals (lead, mercury, cadmium), BPA, phthalate metabolites, PFAS where available
The difference between a standard fertility workup and a comprehensive evaluation is the difference between declaring a crime unsolved and actually investigating it. The causes exist. The question is whether the diagnostic process is designed to find them.
References
- Maraka S, et al. Thyroid Hormone Therapy for Subclinical Hypothyroidism and Infertility: A Systematic Review. Thyroid. 2018;28(6):739-745. doi:10.1089/thy.2017.0645
- Agarwal A, et al. Sperm DNA Fragmentation: A Critical Assessment of Clinical Significance. Andrologia. 2023;55(S1):e14350. doi:10.1111/and.14350
- Chan J, et al. Preconception 25-Hydroxyvitamin D and Fecundability: A Prospective Cohort Study. Hum Reprod. 2022;37(2):228-237. doi:10.1093/humrep/deab283
- Practice Committee of the American Society for Reproductive Medicine. Diagnostic Evaluation of the Infertile Male: A Committee Opinion. Fertil Steril. 2015;103(3):e18-e25. doi:10.1016/j.fertnstert.2014.12.052
- Roeters van Lennep JE, et al. Mechanisms of Unexplained Infertility: A Systematic Review. Reprod Biomed Online. 2022;44(5):823-835. doi:10.1016/j.rbmo.2022.01.012
Medical Disclaimer
This article is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare provider before initiating, modifying, or discontinuing any medical intervention. The information presented reflects current evidence and clinical observations but should not replace individualized medical care.
For structured protocols and implementation guidance, visit Human Optimization Lab.
